Chinese Drugmaker’s IPO Tests a Slumping Biotech Market

  • 📰 WSJ
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 63%

Indonesia Berita Berita

Indonesia Berita Terbaru,Indonesia Berita utama

“Anytime you have companies without earnings, people value them based on sentiment.” Investors are still trying to understand the Chinese biotech sector.

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 98. in İD
 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

Chinese market slump tests index-crafter nervesPlans by FTSE Russell and MSCI to expose a fresh $76 bln to mainland stocks look shaky as Shanghai out-swoons New York. If Beijing reacts clumsily, as in 2015 when it allowed shares to be halted and attacked traders, sceptical investors could be emboldened to revolt.
Sumber: Breakingviews - 🏆 470. / 51 Baca lebih lajut »